TuisAUROPHARMA • NSE
add
Aurobindo Pharma Ltd
Vorige sluiting
₹1 161,40
Dagwisseling
₹1 154,55 - ₹1 182,70
Jaarwisseling
₹958,50 - ₹1 592,00
Markkapitalisasie
682,70 mjd INR
Gemiddelde volume
1,17 m
P/V-verhouding
19,18
Dividend-opbrengs
-
Primêre beurs
NSE
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (INR) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 77,96 mjd | 7,99% |
Bedryfskoste | 34,02 mjd | 13,51% |
Netto inkomste | 8,17 mjd | 7,95% |
Netto winsgrens | 10,48 | -0,10% |
Wins per aandeel | 14,00 | 9,12% |
EBITDA | 15,77 mjd | 16,15% |
Effektiewe belastingkoers | 32,34% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (INR) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 68,68 mjd | -3,93% |
Totale bates | 480,94 mjd | 9,50% |
Totale aanspreeklikheid | 172,09 mjd | 9,41% |
Totale ekwiteit | 308,85 mjd | — |
Uitstaande aandele | 583,84 m | — |
Prys om te bespreek | 2,20 | — |
Opbrengs op bates | — | — |
Opbrengs op kapitaal | 7,81% | — |
Kontantvloei
Netto kontantverandering
| (INR) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 8,17 mjd | 7,95% |
Kontant van bedrywe | — | — |
Kontant van beleggings | — | — |
Kontant van finansiering | — | — |
Netto kontantverandering | — | — |
Beskikbare kontantvloei | — | — |
Meer oor
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer. Wikipedia
Gestig
1986
Hoofkwartier
Webwerf
Werknemers
26 015
